Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
针对硫芥毒性的新型抗氧化疗法 (U54)
基本信息
- 批准号:7294907
- 负责人:
- 金额:$ 148.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-29 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Description (provided by applicant): Sulfur mustard (HD, mustard gas) is the most highly utilized chemical weapon in history, and currently it poses a serious threat to both military and civilian populations. In addition to stockpiles, HD remains one of the easiest chemical weapons to make in large quantities, and it is included in the list of likely choices for terrorist organizations. HD can be a severely debilitating agent for those exposed to it. The primary organs affected by HD are the lungs, skin and eyes. It results in acute airway edema, ARDS, bronchopneumonia, tracheobronchomalacia and/or airway stenosis, bronchiolitis obliterans, bronchiectasis, pulmonary fibrosis, asthma, and other respiratory complications. There are no specific treatments or antidotes for HD nor preventive medications to minimize its effects. Decontamination and supportive care are the only interventions recommended by current medical guidelines and more of these protect the airways. Decontamination is effective for skin and eyes only if enacted very early (< 5 minutes). Unfortunately, recognition of the problem usually does not occur within this timeframe. We hypothesize that supplementation or augmentation of airway mono- or dithiols will prevent or limit sulfur mustard toxicity. Using an animal model employing 2-chloroethyl ethyl sulfide (CEES, "half-mustard"), a less toxic analog of sulfur mustard, we will: 1) Determine airway inflammation, pro-inflammatory cytokines, and principal thiols following half-mustard aerosolization in rat, 2) evaluate effectiveness of oral and aerosolized mono- (GSH) and dithiols (lipoic acid, thioredoxin) in attenuating halfmustard lung injury (inflammation, cytokines, thiols), 3) develop novel compounds to stimulate mono- and dithiol efflux into lung epithelial lining fluid, and 4) examine the efficacy of these novel compounds in vivo. The latter studies will help us establish optimal compounds, route and mode of delivery, pharmacokinetics, bioavailability, and toxicology. Our laboratories have exceptional experience in measurement of the relevant, potentially protective thiol compounds to be evaluated. We anticipate these studies will lead to testing of the most effective compounds using authentic mustard gas at appropriate facilities.
描述(申请方提供):硫芥子气(HD,芥子气)是历史上使用率最高的化学武器,目前对军事和平民都构成严重威胁。除了库存,HD仍然是最容易大量制造的化学武器之一,并被列入恐怖组织可能选择的名单。对于暴露于HD的人来说,HD是一种严重的衰弱剂。受HD影响的主要器官是肺、皮肤和眼睛。它导致急性气道水肿、ARDS、支气管扩张、气管支气管软化和/或气道狭窄、闭塞性细支气管炎、支气管扩张、肺纤维化、哮喘和其他呼吸系统并发症。没有特定的治疗方法或解毒剂,也没有预防性药物,以尽量减少其影响。净化和支持性护理是目前医疗指南推荐的唯一干预措施,其中更多的是保护气道。去污只有在非常早的时候(< 5分钟)才对皮肤和眼睛有效。不幸的是,问题的认识通常不会在这个时间范围内发生。我们假设补充或增加气道单硫醇或二硫醇将预防或限制硫芥毒性。使用使用2-氯乙基乙基硫醚的动物模型,(CEES,“半芥末”),一种毒性较小的硫芥子气类似物,我们将:1)在大鼠中测定半芥子气雾化后的气道炎症、促炎细胞因子和主要硫醇,2)评估口服和雾化的单(GSH)和二硫醇的有效性硫氧还蛋白减轻半芥子气肺损伤(炎症、细胞因子、硫醇),3)开发新的化合物以刺激单硫醇和二硫醇流出到肺上皮衬里液中,和4)检查这些新化合物在体内的功效。后者的研究将帮助我们建立最佳的化合物,给药途径和方式,药代动力学,生物利用度和毒理学。我们的实验室在测量待评估的相关、潜在保护性硫醇化合物方面拥有卓越的经验。我们预计这些研究将导致在适当的设施中使用真实的芥子气测试最有效的化合物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl W White其他文献
CXCL17 induces activation of human mast cells via MRGPRX2
CXCL17 通过 MRGPRX2 诱导人类肥大细胞激活
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Jie Ding;Christina Hillig;Carl W White;Nithya A Fernandopulle;Holly Anderton;Johannes S Kern;Michael P. Menden;Graham A Mackay - 通讯作者:
Graham A Mackay
3 ROS : reactive oxygen species RT-qPCR : reverse transcription quantitative PCR SM : sulfur mustard SpO 2 : peripheral oxygen saturation tPA : tissue plasminogen activator
3 ROS : 活性氧 RT-qPCR : 逆转录定量 PCR SM : 硫芥 SpO 2 : 外周血氧饱和度 tPA : 组织纤溶酶原激活剂
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Heidi J. Nick;Carly A Johnson;Amber R. Stewart;Sarah Christeson;A. Leslie;Bloomquist;Amanda S. Appel;A. Donkor;L. Veress;B. Logue;E. Preston;Bratcher;Carl W White - 通讯作者:
Carl W White
Carl W White的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl W White', 18)}}的其他基金
New Developments in Chemical Countermeasures: CounterACT 2018
化学对抗新进展:CounterACT 2018
- 批准号:
9490163 - 财政年份:2016
- 资助金额:
$ 148.46万 - 项目类别:
Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension
新生儿肺动脉高压的缺氧诱发因素
- 批准号:
8214146 - 财政年份:2011
- 资助金额:
$ 148.46万 - 项目类别:
CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY
高氧线粒体损伤的关键目标
- 批准号:
7716163 - 财政年份:2008
- 资助金额:
$ 148.46万 - 项目类别:
Novel therapeutics for vesicants and toxic inhaled chemicals (U54)
针对出疱剂和有毒吸入化学品的新型疗法 (U54)
- 批准号:
8737370 - 财政年份:2006
- 资助金额:
$ 148.46万 - 项目类别:
相似海外基金
A Novel Anti-inflammatory and Anti-oxidant Therapy for Treating Non-healing Diabetic Foot Ulcers
一种治疗不愈合糖尿病足溃疡的新型抗炎和抗氧化疗法
- 批准号:
10600900 - 财政年份:2022
- 资助金额:
$ 148.46万 - 项目类别:
Development of a novel therapy for the treatment of age-related macular degeneration
开发治疗年龄相关性黄斑变性的新疗法
- 批准号:
10545419 - 财政年份:2022
- 资助金额:
$ 148.46万 - 项目类别:
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma
具有降低眼压和神经保护作用的新型混合分子可用于治疗青光眼
- 批准号:
10477236 - 财政年份:2020
- 资助金额:
$ 148.46万 - 项目类别:
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma
具有降低眼压和神经保护作用的新型混合分子可用于治疗青光眼
- 批准号:
10684092 - 财政年份:2020
- 资助金额:
$ 148.46万 - 项目类别:
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma
具有降低眼压和神经保护作用的新型混合分子可用于治疗青光眼
- 批准号:
10226000 - 财政年份:2020
- 资助金额:
$ 148.46万 - 项目类别:
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma
具有降低眼压和神经保护作用的新型混合分子可用于治疗青光眼
- 批准号:
9887870 - 财政年份:2020
- 资助金额:
$ 148.46万 - 项目类别:
SIRTUIN1-mediated inhibition of p66shc lysine acetylation as a novel treatment for diabetic vasculopathy
SIRTUIN1 介导的 p66shc 赖氨酸乙酰化抑制作为糖尿病血管病变的新型治疗方法
- 批准号:
9272262 - 财政年份:2016
- 资助金额:
$ 148.46万 - 项目类别:
SIRTUIN1-mediated inhibition of p66shc lysine acetylation as a novel treatment for diabetic vasculopathy
SIRTUIN1 介导的 p66shc 赖氨酸乙酰化抑制作为糖尿病血管病变的新型治疗方法
- 批准号:
9135028 - 财政年份:2016
- 资助金额:
$ 148.46万 - 项目类别:
Thio-dependent Antioxidants: A Novel Drug Target for Toxoplasma Gondii
硫代依赖性抗氧化剂:弓形虫的新药物靶点
- 批准号:
8849347 - 财政年份:2014
- 资助金额:
$ 148.46万 - 项目类别:
Augmenting carbon nanoparticles as novel antioxidants for ischemic stroke
增强碳纳米颗粒作为治疗缺血性中风的新型抗氧化剂
- 批准号:
8701712 - 财政年份:2014
- 资助金额:
$ 148.46万 - 项目类别: